Adalimumab reduces inflammation markers in patients with psoriasis

How to stop Hepatitis C from spreading?
July 17, 2018
Huntington’s Disease, Rheumatoid Arthritis Connection
July 17, 2018
Show all

Adalimumab reduces inflammation markers in patients with psoriasis

The medication adalimumab helps with psoriasis.

Patients with psoriasis who were treated with adalimumab had a reduction in key markers of inflammation such as glycoprotein acetylation compared with those treated with phototherapy, according to a study published in Circulation: Cardiovascular Imaging.

“[Tumor necrosis factor, interleukin-6, C-reactive protein and glycoprotein acetylation] are known to predict future cardiovascular events, and thus reducing these markers of inflammation suggests a cardioprotective effect,” Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology, vice chair of clinical research, medical director of the dermatology clinical studies unit, director of the psoriasis and phototherapy treatment center and senior scholar at the Center for Clinical Epidemiology and Biostatistics at University of Pennsylvania Perelman School of Medicine, told Cardiology Today. “However, we did not see any changes in aortic vascular inflammation, and longer-term treatment was associated with mild impairments in HDL.”

Psoriasis treatments

Nehal N. Mehta, MD, MSCE, FAHA, chief of the laboratory of inflammation and cardiometabolic diseases at the NHLBI, and colleagues analyzed data from 97 patients with psoriasis who were assigned subcutaneous injections of adalimumab (Humira, AbbVie; n = 33; mean age, 44 years; 27% women), placebo injections (n = 31; mean age, 44 years; 35% women) or narrowband ultraviolet B phototherapy (n = 33; mean age, 42 years; 30% women). Patients had psoriasis for at least 6 months or moderate to severe psoriasis for at least 2 months. Exclusion criteria included those who received certain treatments for psoriasis before baseline.

An open-label extension started at week 12 for eligible patients. Patients assigned phototherapy were treated with adalimumab for 52 weeks, and those assigned adalimumab continued the same treatment for 40 weeks.

The primary outcome was change in vascular inflammation.

At 12 weeks, vascular inflammation did not change in patients assigned adalimumab compared with placebo (0.64%; 95% CI, –5.84 to 7.12) or the phototherapy group (–1.6%; 95% CI, –6.78 to 3.59). Vascular inflammation remained unchanged at 52 weeks compared with baseline in patients assigned adalimumab (0.02%; 95% CI, –2.85 to 2.9).

Inflammation markers

Patients assigned adalimumab had a reduction in inflammation, as shown by tumor necrosis factor-alpha, CRP, glycoprotein acetylation and interleukin-6. The phototherapy group only had reductions in interleukin-6 and CRP.

Those assigned adalimumab also had a reduction in glycoprotein acetylation and tumor necrosis factor at 12 and 52 weeks.

Read on: Adalimumab reduces inflammation markers in patients with psoriasis


The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.